Skip to main content

CORRECTION article

Front. Pharmacol., 25 May 2023
Sec. Inflammation Pharmacology
Volume 14 - 2023 | https://doi.org/10.3389/fphar.2023.1220144

Corrigendum: Prostaglandin reductase 1 as a potential therapeutic target for cancer therapy

This article is a correction to:

  1. Prostaglandin Reductase 1 as a Potential Therapeutic Target for Cancer Therapy

    1. Read original article
Xing Wang,Xing Wang1,2Guobing Yin Guobing Yin1*Wei ZhangWei Zhang2Kunling SongKunling Song2Longbin ZhangLongbin Zhang2Zufeng Guo Zufeng Guo2*
  • 1Department of Breast and Thyroid Surgery, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
  • 2Center for Novel Target and Therapeutic Intervention, Institute of Life Sciences, Chongqing Medical University, Chongqing, China

A Corrigendum on
Prostaglandin reductase 1 as a potential therapeutic target for cancer therapy

by Wang X, Yin G, Zhang W, Song K, Zhang L and Guo Z (2021). Front. Pharmacol. 12:717730. doi: 10.3389/fphar.2021.717730

In the published article, an author name was incorrectly written as Kunlin Song. The correct spelling is Kunling Song.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: PTGR1, tumor metabolism, eicosanoid pathways, cancer therapeutics, inhibitor

Citation: Wang X, Yin G, Zhang W, Song K, Zhang L and Guo Z (2023) Corrigendum: Prostaglandin reductase 1 as a potential therapeutic target for cancer therapy. Front. Pharmacol. 14:1220144. doi: 10.3389/fphar.2023.1220144

Received: 10 May 2023; Accepted: 18 May 2023;
Published: 25 May 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Wang, Yin, Zhang, Song, Zhang and Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Guobing Yin, yinguobing@cqmu.edu.cn; Zufeng Guo, guozufeng@hotmail.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.